What are the NCCN treatment guidelines for castration-resistant prostate cancer (CRPC) without distant metastasis?

Updated: Jul 31, 2017
  • Author: Bagi RP Jana, MD; more...
  • Print


Enrollment in clinical trial is preferred

Observation is acceptable

Secondary hormone therapy can be considered for patients with prostate-specific antigen (PSA) doubling < 10 months; anti-androgen therapy is acceptable for patients who previously received medical or surgical castration, ketoconazole, corticosteroids, diethylstilbestrol or other estrogens

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!